Chelsea Therapeutics (CHTP) Slides 73% On Huge Volume
Chelsea Therapeutics (CHTP) is off 73% to $1.85, near its 52-week low. The period high is $7.51.
The firm said top-line results from Study 302, the first of two Phase III trials of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). While Study 302 demonstrated that Droxidopa showed a strong symptomatic benefit during the open-label dose titration and run-in phase of the trial, a preliminary review of the data indicates it did not demonstrate a statistically significant improvement relative to placebo, as measured by the mean score of Item 1 (dizziness or light-headedness) of the Orthostatic Hypotension Symptom Assessment (OHSA) during the double-blind phase of trial, the study’s primary endpoint. Droxidopa was safe and well tolerated, with no significant related adverse events reported.
In other words, the trial was a failure.
Douglas A. McIntyre
